Nectin Therapeutics is developing a pipeline of novel monoclonal antibodies and antibody–drug conjugates that target the nectin pathway to address tumor immune resistance. Its lead candidate, NTX1088, is a first‑in‑class monoclonal antibody directed against PVR (CD155) with multiple mechanisms of action that restore DNAM1 expression and block inhibitory interactions with TIGIT and CD96. NTX1088 demonstrated superior antitumor activity in preclinical models and had a favorable safety profile in non‑human primates. NTX1088 is currently being studied in patients with advanced and metastatic solid tumors. Nectin has entered a collaboration with the Myeloma Investment Fund to evaluate NTX1088 as a potential therapy for multiple myeloma. The company describes itself as venture‑backed and privately held and has raised over $33M to date. Its board and management are presented as having deep oncology drug‑development experience. Nectin Therapeutics Ltd. develops novel targeted immunotherapies aimed at addressing resistance to approved immune-oncology treatments. Its lead program, NTX1088, is a first-in-class high‑affinity monoclonal antibody that blocks PVR (CD155) to restore DNAM1 and inhibit TIGIT- and CD96-mediated immune suppression. The company is also advancing a pipeline of targeted immunotherapies and ADCs. Nectin has dosed the first patient in a first-in-human Phase 1 trial of NTX1088 at MD Anderson, with the study planned to include up to 90 patients across dose-escalation and expansion stages and testing both monotherapy and combination with a PD1 blocker. The trial is supported by an investment from the Cancer Focus Fund, LP. Nectin recently extended its Series A financing to over $25 million to support the ongoing clinical evaluation of NTX1088 and further advance its pipeline; IBF and Peregrine Ventures led the extension, with participation from aMoon Fund and other existing investors. Nectin Therapeutics develops targeted immune‑oncology therapies leveraging insights into the nectin pathway, with a pipeline of novel monoclonal antibodies and antibody‑drug conjugates. Its lead program, NTX1088, is a high‑affinity monoclonal antibody directed against PVR that blocks TIGIT and CD96 signaling while restoring DNAM1 (CD226) expression and immune function. NTX1088 is intended to increase anti‑tumor immune effects from activated T cells and natural killer (NK) cells in the tumor microenvironment. The company plans to use the new funding to advance a Phase 1 clinical trial of NTX1088 in patients with locally advanced and metastatic solid tumors, with enrollment expected around mid‑2022. Nectin is venture‑backed and privately held, led by CEO Fabian Tenenbaum, and has been funded by aMoon Fund, Peregrine Ventures, Integra Holdings and Cancer Focus Fund. The company is based in Jerusalem, Israel, and Fort Lee, New Jersey.

Total raised

$30M

Funding rounds

3

Latest round

Series A

Latest activity

Nov 2022